Goldman Sachs
TSBX

Goldman Sachs’s Turnstone Biologics TSBX Stock Holding History

Goldman Sachs’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,518
Closed -$10.2K – 6402
2024
Q4 		$10.2K Buy
+20,518
New +$10.1K ﹤0.01% 5930
2024
Q3 		– Sell
-73,288
Closed -$192K – 6073
2024
Q2 		$192K Buy
+73,288
New +$209K ﹤0.01% 5280

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's TSBX Position: Q1 2025 in Review

Goldman Sachs sold out of Turnstone Biologics (TSBX) in Q1 2025, closing a stake of 20,518 shares — an estimated $10.2K sold.

Goldman Sachs first reported a position in TSBX in Q2 2024 and held it in 2 quarters. The position peaked at $192K in Q2 2024. 23 funds tracked by Wall St. Rank hold TSBX as of Q1 2025.

  • Goldman Sachs reported no remaining Turnstone Biologics position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 20,518 Turnstone Biologics shares in Q1 2025, an estimated $10.2K.
  • Goldman Sachs first reported a position in Turnstone Biologics in Q2 2024 and held it in 2 quarters.
  • Goldman Sachs's Turnstone Biologics position peaked at $192K in Q2 2024.
  • 23 funds tracked by Wall St. Rank held Turnstone Biologics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.